Canada markets close in 2 hours 27 minutes

Kezar Life Sciences, Inc. (2KZ.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
9.75-0.45 (-4.41%)
As of 08:00AM CEST. Market open.
Full screen
Previous Close10.20
Open9.75
Bid9.60 x 0
Ask9.70 x 0
Day's Range9.75 - 9.75
52 Week Range4.20 - 16.50
Volume900
Avg. Volume34
Market Cap589.833M
Beta (5Y Monthly)0.16
PE Ratio (TTM)N/A
EPS (TTM)-0.99
Earnings DateAug 10, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.75
  • Business Wire

    Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., August 03, 2022--Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that, in connection with the previously announced appointment of Nick Mordwinkin, Pharm.D., Ph.D., as the Company’s Chief Business Officer, the Compensation Committee of the company’s Board of Directors granted Dr. Mordwinkin a nonqualified stock option to purc

  • Zacks

    Wall Street Analysts See an 82% Upside in Kezar Life Sciences, Inc. (KZR): Can the Stock Really Move This High?

    The mean of analysts' price targets for Kezar Life Sciences, Inc. (KZR) points to an 81.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

  • Business Wire

    Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position

    SOUTH SAN FRANCISCO, Calif., July 11, 2022--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the appointment of Nick Mordwinkin, Pharm.D., Ph.D., as Chief Business Officer. Dr. Mordwinkin will be key to the next stage of Kezar’s growth and will be responsible for shaping the company’s business development strategy.